Open label extension study of lanreotide Autogel 120 mg in patients with non functioning entero-pancreatic endocrine tumour The primary objective is to assess the long term safety of administration of lanreotide Autogel 120 mg every 28 days in patients with non functioning entero-pancreatic neuro endocrine tumour.

• Country None
• organs None
• Specialty None

A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMICALLY CONTROLLED ON THE LONG TERM TREATMENT WITH OCTREOTIDE LAR 10 OR 20 MG To evaluate the efficacy of extended injection intervals (every 6 or 8 weeks) of lanreotide Autogel 120 mg in the control of insulin-like growth factor-1 (IGF-1) levels in adult subjects with acromega...

• Country None
• organs None
• Specialty None

This study will aim to assess how effective the next generation of BTX-A-HAC (BTX-A-HAC NG) with an injectable liquid formulation is for improving the appearance of lines (wrinkles) between the eyebrows (glabellar area) The primary study objective is to demonstrate the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX A HAC; hereafter referre...

• Country None
• organs None
• Specialty None

Phase III, multicentre study assesssing the long term safety and and efficay of repeated treatments with Dysport in the treatment of arm spasticity in adult patients with hemiparesis The primary study objective is to assess the long term safety of Dysport in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.

• Country None
• organs None
• Specialty None

A phase III, placebo controlled clinical trial to assess efficacy and safety of one dose of Dysport solution in the treatment of upper limb spasticity in adults after stroke To assess the efficacy of Dysport Solution 1000 U compared to placebo in reducing the upper limb muscle tone (using the Modified Ashworth Scale (MAS)) in adult subjects with upper limb spastic hemipar...

• Country None
• organs None
• Specialty None

Étude D-FR-01087-001 : étude de phase 1-2 évaluant la sécurité d’emploi, la tolérance, la biodistribution et l’efficacité du 177Lu-3BP-227 chez des patients ayant des tumeurs solides exprimant le récepteur 1 de la neurotensine. Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90 % des cancers humains. La neurotensine...

• Country France
• organs Tumeurs solides
• Specialty Thérapies Ciblées

Phase III, multicentre, non comparative, open and single stage study to assess the efficacy and safety of pamoate of triptorelin 11.25 mg in children with precocious puberty To assess the efficacy of Triptorelin 11.25 mg pamoate with respect to the proportion of children with suppressed LH response (LH < or = 3 UI/l) to GnRH test performed 3 months (M3) after injection wi...

• Country None
• organs None
• Specialty None

The study investigates the new subcutaneous application of Triptorelin pamoate (Pamorelin® LA 11.25 mg) versus the intramuscular application in patients with advanced prostate cancer The main objective of the trial is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-8...

• Country None
• organs None
• Specialty None

Phase IIIB, Double Blind, Placebo Controlled, International, Multicenter, Parallel Group Study, to Assess the Efficacy and Safety of Testim Gel in Combination with a Phosphodiesterase V Inhibitor (Tadalafil), in Male Patients with Low or <Borderline> Baseline Serum Testosterone Levels and Erectile Dysfunction To demonstrate that in patients with erectile dysfunction (ED) who are found to have low (<8 nmol/L or 231 ng/dL) or <borderline> (<12 nmol/L or 346 ng/dL) baseline total testosterone levels, Testim G...

• Country None
• organs None
• Specialty None

A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in patients with prostate cancer Part A: To determine the proportion of patients remaining medically castrated (serum testosterone level < 50 ng/dL) at Day 240 following two SC administrations of a 4-month sustained-release (SR) form...

• Country None
• organs None
• Specialty None